This clinical policy from the American College of Emergency Physicians addresses key issues in the evaluation and management of adult patients presenting to the emergency department with acute carbon monoxide poisoning. A writing subcommittee conducted a systematic review of the literature to derive evidence-based recommendations to answer the following clinical questions: 1) In emergency department patients with suspected acute carbon monoxide poisoning, can noninvasive carboxyhemoglobin measurement be used to accurately diagnose carbon monoxide toxicity? 2) In emergency department patients diagnosed with acute carbon monoxide poisoning, does hyperbaric oxygen therapy as compared with normobaric oxygen therapy improve long-term neurocognitive outcomes? 3) In emergency department patients diagnosed with acute carbon monoxide poisoning, can cardiac testing be used to predict morbidity or mortality? Evidence was graded and recommendations were made based on the strength of the available data. MEDLINE InProcess, Scopus, Web of Science, and the Cochrane Database were performed. All searches were
INTRODUCTION
There are approximately 50,000 emergency department (ED) visits per year as a result of carbon monoxide (CO) poisoning. 1 Although many of these are nonfatal exposures with various degrees of toxicity, an estimated 1,000 to 2,000 patients a year die from severe toxicity. 1 However, given that CO is a colorless, odorless gas often with nonspecific toxicologic symptoms, these numbers are likely skewed by misdiagnosis. Thus, the true morbidity and mortality rates are probably considerably higher. 2, 3 As discussed in the 2008 published American College of Emergency Physicians (ACEP) clinical policy, "Clinical Policy: Critical Issues in the Management of Adult Patients Presenting to the Emergency Department with Acute Carbon Monoxide Poisoning," 4 the mechanism of toxicity is known to be multifactorial, resulting from impaired oxygen delivery to highly metabolic tissues (eg, brain, heart), induced altered function of critical proteins (eg, myoglobin, mitochondrial cytochrome oxidase), toxic free radical formation, and other less well understood actions. 4, 5 Acute poisoning has an extremely varied presentation, from minimal symptomatology to unresponsiveness, hypotension, severe acidemia, or acute respiratory failure. Tissues with high metabolic needs are particularly at risk for dysfunction and injury. Classic presentations involve vague complaints of headache, dizziness, nausea, vomiting, shortness of breath, and/or chest pain. 6 Beyond acute toxicity, CO poisoning is known to be associated with longer-term morbidity and mortality. Neurologic sequelae (either persistent from the time of exposure or delayed in onset by 2 to 21 days) have been described in 12% to 68% of poisoned patients. [7] [8] [9] [10] [11] [12] [13] These sequelae tend to be typified by memory loss, impaired concentration or language, changes in affect such as depression, or parkinsonism and can spontaneously resolve or result in lifelong disability. However, virtually any neurologic abnormality can result from severe CO poisoning. Furthermore, poisoned patients have been shown to have up to a 3-fold increase in mortality compared with matched, unexposed individuals at a median follow-up of 7.6 years after their exposure. 14 CO binds hemoglobin with an affinity approximately 220 times that of oxygen, which results in an elimination half-life in the body of 4 to 5 hours in the absence of therapy. 15 Oxygen therapy, whether administered normobarically by high-flow nonrebreathing face mask or hyperbarically by high-pressure chamber, has been shown to decrease the elimination half-life of CO to 85 minutes (range, 26 to 148 minutes) 16 and 20 minutes, respectively. 16, 17 Considerable attention has been paid in the literature to the role of hyperbaric oxygen (HBO 2 ) over normobaric oxygen as a potentially beneficial therapeutic option for acute toxicity and as a means of reducing longterm sequelae; despite this, the role of HBO 2 remains controversial. 4, 18 The 2008 ACEP clinical policy 4 addressed critical questions about the role of HBO 2 therapy and concluded that although HBO 2 is a therapeutic option for COpoisoned patients, its use cannot be mandated. Furthermore, at the time, no clinical variables seemed to identify poisoned patients for whom HBO 2 was most likely to provide benefit. Given the continued controversy surrounding this topic, this policy's revision will revisit the role of HBO 2 , reviewing the literature published since our last recommendations. Additionally, this revision will address the role of noninvasive carboxyhemoglobin (COHb) measurement (pulse CO oximetry) to diagnose CO toxicity in patients with suspected acute CO poisoning and the role of cardiac testing to predict morbidity and mortality.
METHODOLOGY
This clinical policy was created after careful review and critical analysis of the medical literature and was based on a systematic review of the literature. Searches of MEDLINE, limited to English-language sources, human studies, and adults. Specific key words/phrases, years used in the searches, dates of searches, and study selection are identified under each critical question. In addition, relevant articles from the bibliographies of included studies and more recent articles identified by committee members and reviewers were included.
This policy is a product of the ACEP clinical policy development process, including expert review, and is based on the existing literature; when literature was not available, consensus of emergency physicians was used. Expert review comments were received from emergency physicians, hyperbaric medicine specialists, medical toxicologists, the Council of Undersea and Hyperbaric Medicine Fellowship Directors, and the ACEP Undersea and Hyperbaric Medicine Section leadership. The draft was available for comments during a 60-day open-comment period, with notices of the comment period sent in e-mails, published in EM Today, and posted on the ACEP Web site. The responses were used to further refine and enhance this policy; however, the responses do not imply endorsement of this clinical policy. Clinical policies are scheduled for review and considered for revision every 3 years; however, interim reviews are conducted when technology, methodology, or the practice environment changes significantly. ACEP was the funding source for this clinical policy.
Assessment of Classes of Evidence
All articles used in the formulation of this clinical policy were graded by at least 2 methodologists and assigned a Class of Evidence. Each article was assigned a design class, with design 1 representing the strongest study design and subsequent design classes (eg, design 2, design 3) representing respectively weaker study designs for therapeutic, diagnostic, or prognostic clinical reports, or meta-analyses (Appendix A). Articles were then graded on dimensions related to the study's methodological features, such as randomization processes, blinding, allocation concealment, methods of data collection, outcome measures and their assessment, selection and misclassification biases, sample size, and generalizability. Using a predetermined process related to the study's design, methodological quality, and applicability to the critical question, articles received a final Class of Evidence grade (ie, Class I, Class II, Class III, or Class X) (Appendix B). Articles identified with fatal flaws or that were ultimately not applicable to the critical question received a Class of Evidence grade "X" and were not used in formulating recommendations for this policy. Grading was done with respect to the specific critical questions; thus, the level of evidence for any one study may vary according to the question for which it is being considered. As such, it was possible for a single article to receive different Classes of Evidence as different critical questions were answered from the same study. Question-specific Classes of Evidence grading may be found in the Evidentiary Table ( available online at www.annemergmed.com).
Translation of Classes of Evidence to Recommendation Levels
Strength of recommendations regarding each critical question were made by subcommittee members using results from strength of evidence grading, expert opinion, and consensus among subcommittee members according to the following guidelines:
Level A recommendations. Generally accepted principles for patient care that reflect a high degree of clinical certainty (eg, based on evidence from 1 or more Class of Evidence I or multiple Class of Evidence II studies).
Level B recommendations. Recommendations for patient care that may identify a particular strategy or range of strategies that reflect moderate clinical certainty (eg, based on evidence from 1 or more Class of Evidence II studies or strong consensus of Class of Evidence III studies).
Level C recommendations. Recommendations for patient care that are based on evidence from Class of Evidence III studies or, in the absence of any adequate published literature, based on expert consensus. In instances where consensus recommendations are made, "consensus" is placed in parentheses at the end of the recommendation.
There are certain circumstances in which the recommendations stemming from a body of evidence should not be rated as highly as the individual studies on which they are based. Factors such as heterogeneity of results, uncertainty about effect magnitude and consequences, and publication bias, among others, might lead to such a downgrading of recommendations.
When possible, clinically oriented statistics (eg, likelihood ratios [LRs], number needed to treat [NNT]) are presented to help the reader better understand how the results may be applied to the individual patient. For a definition of these statistical concepts, see Appendix C.
This policy is not intended to be a complete manual on the evaluation and management of patients with suspected or diagnosed CO poisoning but rather a focused examination of critical issues that have particular relevance to the current practice of emergency medicine.
It is the goal of the Clinical Policies Committee to provide an evidence-based recommendation when the medical literature provides enough quality information to answer a critical question. When the medical literature does not contain adequate empirical data to answer a critical question, the members of the Clinical Policies Committee believe that it is equally important to alert emergency physicians to this fact.
This clinical policy is not intended to represent a legal standard of care for emergency physicians. Recommendations offered in this policy are not intended to represent the only diagnostic or management options available to the emergency physician. ACEP recognizes the importance of the individual physician's judgment and patient preferences. This guideline defines for the physician those strategies for which medical literature exists to provide support for answers to the critical questions addressed in this policy.
Scope of Application. This guideline is intended for physicians working in EDs.
Inclusion Criteria. This guideline is intended for adult patients presenting to the ED with suspected or diagnosed acute CO poisoning.
Exclusion Criteria. This guideline is not intended to be used for out-of-hospital emergency care patients, pediatric populations, pregnant patients and fetal exposures, those with chronic CO poisoning, or patients with delayed presentations (more than 24 hours after cessation of exposure) of CO poisoning.
For potential benefits and harms of implementing the recommendations, see Appendix D. Study Selection: One hundred thirty-eight articles were identified in the search; 13 articles were selected from the search results for further review, with 5 studies included for this critical question.
CRITICAL QUESTIONS
In patients with suspected CO poisoning, CO exposure has traditionally been measured by co-oximeter analysis of venous or arterial blood for COHb levels. Nontoxic levels vary in the general population, but nonsmokers typically have a blood COHb level of 3% or less, whereas individuals who smoke tobacco have levels up to 10%. In 2005, the Food and Drug Administration first approved a noninvasive pulse CO-oximeter to measure CO saturation (analogous to a fingertip pulse oximeter commonly used for measuring and monitoring oxygen saturation). 19 A pulse CO-oximeter has several potential advantages over traditional blood COHb analysis: pulse CO oximetry is fast, is noninvasive, is capable of continuous measurement, and can assess multiple patients with little additional cost. However, because prompt treatment of CO can prevent disability, a diagnostic test without high sensitivity would not routinely be helpful. As a point of emphasis, the clinical question addressed here, the ability of noninvasive CO oximetry to accurately diagnose suspected CO exposure in ED patients, is a separate clinical question from the utility of noninvasive CO oximetry to screen for CO poisoning in undifferentiated populations of ED patients or in the out-of-hospital setting; for this latter use, a device with a lower sensitivity may still be of benefit. In reviewing the literature to determine the accuracy of noninvasive pulse CO oximetry, 1 Class II 20 and 4 Class III 19,21-23 studies were identified.
In the only Class II study included, Touger et al 20 enrolled 120 ED patients with suspected CO poisoning, each receiving concurrent conventional blood COHb testing and noninvasive COHb testing with a pulse COoximeter. Of these subjects, 23 met the authors' definition of CO toxicity (COHb level !15%) on blood testing. The mean difference between blood and noninvasive COHb values was 1.4% (95% confidence interval [CI] 0.2% to 2.6%); however, in 33.3% of patients, the agreement between the 2 tests exceeded the authors' predefined acceptable range (AE5% COHb). The noninvasive test had a sensitivity of 48% (95% CI 27% to 69%) and a specificity of 99% (95% CI 94% to 100%), yielding a positive LR of 48 (95% CI 4.5 to undefined) and negative LR of 0.5 (95% CI 0.3 to 1.0) for detecting a COHb level greater than 15%. This study had several important limitations, including a low incidence of actual CO poisoning in the study population, unclear reporting of the exact timing of COHb testing, and no identification of smoking status, which can confound the diagnosis of CO poisoning.
Two Class III studies 19, 21 were similarly designed to examine the diagnostic performance of CO oximetry. Sebbane et al 19 measured blood and noninvasive COHb levels in 93 patients in a single ED who had suspected CO toxicity. Although the mean difference in COHb between the 2 tests was small (-0.2% standard deviation [SD] 3.3; 95% limits of agreement -6.7, 6.3), the study had substantial limitations. Only 33% of patients received simultaneous testing, and noninvasive testing was performed before blood testing in 46% of the cohort (mean time difference¼19 minutes) and after blood testing in the remaining 21% (mean time difference was not reported). Additionally, in the setting of asynchronous testing, the decision to perform the second test and thus enroll the patient in the study may have been influenced by the initial test result. In a smaller study, Coulange et al 21 included 12 patients with suspected CO poisoning and compared blood and noninvasive testing in each patient. The authors found a mean difference in COHb level of -1.5% (SD 2.5; 95% limits of agreement -6.4, 3.4). Together these 3 studies do not support the use of noninvasive testing to detect elevated COHb levels among patients with suspected CO poisoning.
Two additional Class III studies 22,23 explored noninvasive CO oximetry with convenience sampling of undifferentiated patients. A 2011 study by Roth et al 22 identified 1,578 patients with noninvasive CO oximetry screening tests who also had blood COHb testing within 60 minutes of the noninvasive measurement. Only 17 of 1,578 study patients received a diagnosis of CO poisoning (1.1%; 95% CI 0.6% to 1.7%), limiting the conclusions that can be drawn from this study. Noninvasive COHb readings in this cohort were 3% higher than blood COHb testing, and the limits of agreement between the 2 tests ranged from -3.6% to 9.5%. Finally, a Class III study by Weaver et al 23 measured simultaneous blood and noninvasive COHb levels in a convenience sample of 1,363 patients and identified CO poisoning in 4 patients (0.3%; 95% CI 0.1% to 0.7%). Although underpowered to provide meaningful data with respect to the accuracy of noninvasive testing for patients with suspected CO toxicity, the noninvasive testing underestimated COHb levels in each of the 4 patients identified as having CO poisoning. In 2 of these 4 cases, the affected patients had relatively lower blood COHb levels (8.7% and 8.4%), and noninvasive testing would not have supported the diagnosis of CO poisoning (noninvasive CO oximetry levels of 4% and 2%, respectively).
Future Research
First, if newer noninvasive devices are developed for the measurement of CO exposure, prospective ED-based studies should focus on patients with suspected acute CO poisoning and perform simultaneous comparison of these devices with conventional testing. Second, in the review of this literature, there were a number of clinical cases of occult CO poisoning identified with the use of noninvasive CO measurement. However, the clinical question addressed by our review involved the diagnostic accuracy of this device. Future studies, using either new data or a systematic review of previous data, should investigate the utility of noninvasive devices to screen for elevated COHb in undifferentiated cohorts of ED patients, especially in unsuspected poisoning.
2.
In ED patients diagnosed with acute CO poisoning, does HBO 2 therapy as compared with normobaric oxygen therapy improve long-term neurocognitive outcomes?
Patient Management Recommendations
Level A recommendations. None specified. Level B recommendations. Emergency physicians should use HBO 2 therapy or high-flow normobaric therapy for acute CO-poisoned patients. It remains unclear whether HBO 2 therapy is superior to normobaric oxygen therapy for improving long-term neurocognitive outcomes.
Level C recommendations. None specified.
Key words/phrases for literature searches: carbon monoxide poisoning, hyperbaric oxygenation, normobaric oxygen therapy, treatment outcome, risk assessment, prognosis, neurologic sequelae, cognition disorders, neurotoxicity, and variations and combinations of the key words/phrases. Searches included January 1, 2006, through the search date of July 21, 2015.
Study Selection: Two hundred sixteen articles were identified in the search; 43 articles were selected from the search results for further review, with 7 studies included for this critical question.
Long-term neurocognitive deficits as a result of CO poisoning, generally referred to as neurologic sequelae, are some of the most feared clinical outcomes of acute CO toxicity. HBO 2 markedly reduces the half-life of COHb and has been postulated to improve neurologic outcomes after severe CO poisoning. 24 There are competing theories from a molecular physiology standpoint about the potential benefit of HBO 2 in reducing lipid peroxidation and the potential risk of cell death from oxygen free radical formation. 25 Despite a significant body of literature on the use of HBO 2 in prevention of neurologic sequelae, its benefits and use in acute CO poisoning remain controversial. For this critical question, all graded medical literature from the 2008 ACEP clinical policy was again reviewed. In addition, an updated literature search was performed. In total, 2 meta-analyses (1 Class II 26 
and 1
Class III 27 ) and 5 original research articles (3 Class II 7,10,11 and 2 Class III 28, 29 ) are used to support the recommendation for this critical question. Four of these studies 7, 10, 11, 29 were extensively discussed in the previously published clinical policy. 4 In 2011, a Class III Cochrane Database meta-analysis of 6 studies investigated the benefit of HBO 2 for the treatment of acute CO poisoning. 27 This review compared trials with an HBO 2 and normobaric arm, assessing neurologic sequelae as the primary outcome. In a total of 1,361 patients across all studies, the odds ratio (OR) for developing neurologic sequelae among patients receiving HBO 2 was 0.78 (95% CI 0.54 to 1.12). The authors noted significant statistical and methodological heterogeneity across the trials and identified biases that may have influenced results in trials with either positive or negative results. One of the positive-result trials did not adjust for multiple hypothesis testing 11 and another may have introduced bias during the trial by changing 1 of their primary endpoints. 7 Of the trials with negative results, 2 were limited by exclusion of severely poisoned patients 28, 29 and 1 by a significant lost-to-follow-up rate. 10 These findings were nearly identical to a 2005 Class II meta-analysis 26 by the same lead author and have considerable overlap with respect to the included studies and data. In this earlier systematic review, 26 6 studies were included, with a total of 1,479 randomized patients. The pooled OR for developing neurologic sequelae across groups was 0.77 (95% CI 0.51 to 1.14). The quality of the articles was carefully evaluated, and the statistical analyses were appropriate, using a randomeffects model and sensitivity analysis. Both of these meta-analyses 26, 27 included individual studies determined to have major methodological flaws by our Class of Evidence grading process (ie, Class X). 13, 30 Both of these meta-analyses concluded that it is unclear whether the addition of HBO 2 improves long-term neurocognitive outcome over treatment with normobaric oxygen.
Each of the remaining clinical trials included in this review 7, 10, 11, 28, 29 was included in at least 1 of the above meta-analyses. Overall, these 5 original research studies 7, 10, 11, 28, 29 demonstrated inconsistent support for the use of HBO 2 for the treatment of acute CO poisoning. Three studies (1 Class II 10 and 2 Class III 28, 29 ) found no benefit, whereas 2 Class II studies 7, 11 reported benefits of HBO 2 therapy for neurocognitive outcomes.
Studies Reporting No Benefit
In a Class II study, Scheinkestel et al 10 randomized 191 patients to HBO 2 or normobaric oxygen with sham treatment and found no statistical difference in neurologic sequelae at 1-month follow-up. A large number of patients (73%) had severe symptoms and many of the patients received multiple (>3) HBO 2 treatments. A significant limitation was the loss of 54% of subjects to follow-up. In addition, many of the patients had a delay to HBO 2 therapy in relation to CO exposure. All patients referred for CO poisoning were eligible regardless of when their CO exposure occurred (mean delay to the administration of HBO 2 therapy¼7.1 hours).
Most recently, a 2011 Class III study, Annane et al 28 randomized 385 acutely poisoned CO patients into 2 trials (A and B) according to whether coma was present at the patient's initial presentation. The primary outcome for both trials was neurologic sequelae as determined by patient questionnaire and physical examination, not formal neuropsychiatric testing. The treatment intervention varied by trial. In trial A (n¼179), patients without coma were randomized to either normobaric oxygen or normobaric oxygen plus 1 session of HBO 2 . In trial B (n¼206), patients with coma were randomized to either normobaric oxygen plus 1 HBO 2 session or normobaric oxygen plus 2 HBO 2 sessions. At interim analysis, trial A showed no benefit with HBO 2 therapy in terms of neurologic sequelae (58% versus 61%; unadjusted OR¼0.90; 95% CI 0.47 to 1.71). Trial B showed a trend toward worse outcomes in the group randomized to receive 2 HBO 2 therapy sessions (47% versus 68%; unadjusted OR¼0.42; 95% CI 0.23 to 0.79; number needed to harm¼5). The study was stopped early, given the concerns for patient harm.
Last, an older Class III study by Raphael et al 29 randomized 629 acutely CO poisoned patients by presence or absence of coma. Noncomatose patients (n¼343) were assigned to receive either HBO 2 or normobaric oxygen, whereas comatose patients (n¼286) were randomized to 1 or 2 HBO 2 therapy sessions. In both study arms, the recovery rates were no different (arm A: 66% control versus 68% HBO 2 therapy; arm B: 52% control versus 54% HBO 2 therapy); however, the study may have been underpowered to detect a true difference (P¼.75 for both arms).
Two additional methodological limitations exist for these studies showing no HBO 2 benefit. 10, 28, 29 First, all 3 studies included patients receiving therapy that was initiated up to 12 hours after their CO exposure. Research suggests the beneficial effects of HBO 2 therapy may diminish significantly with delay to therapy of more than 6 hours from time of exposure. 10, 11, 31, 32 Second, the dose of HBO 2 therapy used in 2 of the studies may have been suboptimal. 28, 29 The studies by Raphael et al 29 and Annane et al 28 used 2 atmospheres absolute (ATA) of pressure during HBO 2 therapy, whereas studies demonstrating benefit have used 2.5 to 3 ATA. Concern has been raised that this dose difference may account for the variability in the point estimates for treatment effect. 33 
Studies Reporting Benefit:
In a 2002 Class II study, Weaver et al 7 reported improved outcomes in patients treated with HBO 2 in a blinded, single-center, randomized clinical trial. Patients in the treatment group were exposed to 3 HBO 2 sessions. The first session used 3 ATA for 1 hour followed by 2 ATA for 1 hour; the remaining sessions used 2 ATA. This study also included patients with HBO 2 therapy initiated up to 24 hours after CO exposure. At 6 weeks after poisoning, HBO 2 was associated with a 21% (95% CI 6% to 34%) absolute reduction in the rate of neurologic sequelae (46% versus 25%; unadjusted OR¼0.39; 95% CI 0.20 to 0.78; NNT¼5). Follow-up was excellent in each arm. The normobaric oxygen group received only 1 sham treatment, whereas the HBO 2 arm received 3 HBO 2 treatments. The major criticism of this study is that during enrollment, a disproportionate number of patients were randomized with cerebellar dysfunction to the control group (15% control versus 4% HBO 2 therapy).
The other study reporting benefit for HBO 2 was a Class II study by Thom et al. 11 This study was a smaller trial (n¼60) of patients who received 1 session of HBO 2 versus 100% normobaric oxygen by face mask. The HBO 2 protocol was 2.8 ATA for 30 minutes followed by 2 ATA for 90 minutes. HBO 2 was associated with a 23% (95% CI 8% to 38%) absolute reduction in the rate of neurologic sequelae (23% versus 0%; unadjusted OR¼0.06; 95% CI 0 to 1.03; NNT¼4.3). This is the only study included in our systematic review in which all of the subjects presented within 6 hours of CO exposure. However, patients with loss of consciousness were excluded, so the cohort was both smaller and less severely poisoned compared with those in other trials. In addition, the outcome assessment for neurologic sequelae was made by nonblinded clinicians.
The current trials vary widely in their interpretation of the utility of HBO 2 for prevention of neurologic sequelae. The lack of standardization across trials (eg, severity of poisoning, timing of initial HBO 2 therapy delivery [<6 versus >6 hours], HBO 2 therapy dose [2 versus 2.5 to 3 ATA], definitions of neurologic outcomes, and follow-up windows) makes drawing any definitive conclusions about the benefit or harm of using HBO 2 therapy for the treatment of acute CO poisoning difficult. Although there are concerns of potential harm (eg, barotrauma, lack of access to immediate medical care while in the chamber, long-distance transfers), it is difficult to determine from the existing data whether these harms outweigh the potential benefits of HBO 2 .
Future Research:
Despite the existing literature on this topic, there are few well-designed clinical trials, and the results of these trials are not conclusive in regard to the efficacy of HBO 2 in preventing neurologic sequelae. An adequately powered multicenter randomized controlled trial with well-defined inclusion criteria, standardized treatment protocols, minimal delay in administration of HBO 2 therapy, and adequate retention for long-term follow-up is needed to definitively answer the question. Ideally, further research should include groups long thought to be at greater risk for neurologic sequelae, such as children and fetuses.
3.
In ED patients diagnosed with acute CO poisoning, can cardiac testing be used to predict morbidity or mortality?
Patient Management Recommendations
Level A recommendations. None specified. Level B recommendations. In ED patients with moderate to severe CO poisoning, obtain an ECG and cardiac biomarker levels to identify acute myocardial injury, which can predict poor outcome.
Key words/phrases for literature searches: carbon monoxide poisoning, acute carbon monoxide poisoning, heart function tests, diagnostic imaging, cardiac testing, echocardiography, radionuclide imaging, brain natriuretic peptide, creatine kinase, biological markers, myoglobin, troponin, tomography, survival or survival rate, prognosis, risk assessment, morbidity, mortality, and variations and combinations of the key words/phrases. Searches included January 1, 1980, through the search date of July 21, 2015.
Study Selection: Ninety-seven articles were identified in the search; 28 articles were selected from the search results for further review, with 2 studies included for this critical question.
CO is known to be cardiotoxic. 34 It is proposed that the gas binds to myoglobin and results in electrical, functional, and morphologic alterations of the heart, affecting patients with and without underlying cardiovascular disease. Toxicity likely occurs not only from direct tissue hypoxia but also because of changes and damage at a cellular level. Studies have shown that acute myocardial injury occurs in 37% to 53% of patients with acute CO poisoning. 14, 35, 36 Typically, this injury is determined by abnormal laboratory test results (eg, elevated creatine kinase or troponin level) or ischemic electrocardiographic changes; some authors have specifically examined the T wave as an indicator. 37 It has been proposed that identifying cardiotoxicity might inform health care providers making treatment and follow-up decisions or considering an exposed patient's risk for morbidity and mortality; as such, authors have investigated whether cardiac testing can predict morbidity or mortality. 14, 36, 37 In 2006, Henry et al (Class II) 14 published the only prospective study examining long-term mortality in patients poisoned with CO who demonstrated acute myocardial injury at the time of their exposure. In this study, 230 patients with moderate to severe poisoning were followed for a median of 7.6 years. Baseline data, including but not limited to the severity of presentation, hospital length of stay, ischemic changes on ECG, and presenting cardiac enzyme levels, were collected and compared with mortality rates to determine independent predictors of long-term mortality in CO-poisoned patients. Mortality rates were compared with those from matched national mortality data. Enrolled subjects had a mean age of 47 years and a low incidence of comorbidities. Despite a selection bias toward more severely poisoned patients (ie, 100% received HBO 2 therapy, 81% had transient or persistent loss of consciousness, 52% were intubated, 12% required lidocaine or nitroglycerine, and 6% required pharmacologic blood pressure support), only 5% (12 patients) experienced inhospital mortality; yet 24% died in the out-of-hospital setting during follow-up, which is 3 times the rate of matched national mortality data for unexposed patients. Among subjects with myocardial injury on enrollment, 38% died during follow-up compared with 15% of patients without myocardial injury. Equally notable was that the percentage of deaths from cardiac causes was significantly different (44% versus 18%). Multivariable analysis showed acute myocardial injury (adjusted hazard ratio¼2.1; 95% CI 1.2 to 3.7) to be independently predictive of mortality even after a supplementary propensity score analysis (adjusted hazard ratio¼1.90; 95% CI 1.02 to 3.37) controlled for baseline characteristics (eg, age, sex, diabetes, hypertension, tobacco use, previous cardiac disease). Thus, CO-poisoned patients with acute cardiac injury on presentation had significantly higher long-term mortality and were more likely to have their mortality attributed to a cardiac cause.
In 2015, Shen et al 36 (Class III) also found acute myocardial injury to be the only independent predictor of poor outcome (OR¼2.8; 95% CI 1.2 to 6.5) in 148 intentionally poisoned patients with acute respiratory failure who underwent HBO 2 therapy. Poor outcome was defined as inhospital mortality or neurologic sequelae.
Other variables associated with poor outcome but not independently predictive included hypotension, WBC count, aspartate amino transferase levels, blood urea nitrogen level, and time from ED arrival to initiation of treatment.
Future Research
Future research addressing acute myocardial injury from CO poisoning should focus on the role of cardiac testing and subsequent intervention in a less severely poisoned population. Additionally, studies could investigate the role of more aggressive initial and long-term cardiac management in patients known to be at higher risk for morbidity and mortality after CO toxicity.
Relevant industry relationships: There were no relevant industry relationships disclosed by the subcommittee members for this topic.
Relevant industry relationships are those relationships with companies associated with products or services that significantly impact the specific aspect of disease addressed in the critical question.
